SRC Family Kinase Inhibitor as a Potential Treatment for Fragile X Syndrome

This $100,000 FRAXA grant will fuel the Smith lab’s new approach to treating Fragile X syndrome using Saracatinib, originally a cancer drug.

Read More »

Categories

FRAXA Funded Research

Current Research Grants (38)